With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents that bring enhanced safety and efficacy. Exton, PA August 31, 2023 – The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent autoimmune history. With the entry […]
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
After early adoption, overall use of Olumiant in alopecia areata is beginning to level-off, according to Spherix Global Insights Exton, PA, July 11, 2023 – In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia areata (AA). At one-year post approval, perceptions of the […]
Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low
April 3, 2023 Skylar Jeremias Although rheumatologists, dermatologists, and gastroenterologists rated their awareness of adalimumab biosimilars as high, a significant proportion of each group reported that they were not confident prescribing a biosimilar over the originator. Although rheumatologists, dermatologists, and gastroenterologists rated their awareness of adalimumab biosimilars as high, a significant proportion of each group […]
Aided by “Clean” FDA Label, US Dermatologists Report BMS’ Sotyktu Has Potential to Delay Biologic Treatment in Plaque Psoriasis, According to Spherix Global Insights
Amgen’s Otezla likely to face the most immediate impacts of increased Sotyktu adoption EXTON, Pa., December 8, 2022 /PRNewswire/ — On September 9, 2022, BMS announced the FDA approval of Sotyktu for moderate-to-severe plaque psoriasis (PsO), making it the first selective TKY2 inhibitor available in the US to treat the disease. In October 2022, Spherix began […]
Eli Lilly’s Olumiant is Filling a Critical Gap for Severe Alopecia Areata Patients, According to Spherix Global Insights
Despite highly favorable perceptions of the first approved treatment, dermatologists’ desire increased support from Eli Lilly sales representatives EXTON, Pa., November 17, 2022 /PRNewswire/ — On June 13, 2022, Eli Lilly announced the FDA approval of Olumiant for severe alopecia areata (AA), making it the first systemic therapy available in the US to treat the disease. […]
Economic Burden Forces Shift in Specialty Physicians’ Treatment Decisions and Relationship with Pharma, According to New Spherix Report
The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and increased patient sensitivity to medication costs EXTON, Pa., September 12, 2022 /PRNewswire/ — Over the past year, many countries have reported multi-decade highs in inflation, with the United States recording its highest inflation rate in […]
Implications of Expanded Biosimilar Use in the United States’ Dermatology, Gastroenterology, and Rheumatology Markets Highlighted in New Spherix Study
232 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., July 7, 2022 /PRNewswire/ – Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products), with no clinically meaningful efficacy and safety differences from […]
US Dermatologists’ Lack of Success with Current Treatment Options in Vitiligo Paves the Way for Pipeline Advanced Systemic Agents to Disrupt the Market, According to Spherix Global Insights
Dermatologists are most enthused about the potential utility of the JAK inhibitor class, including Incyte’s Opzelura, AbbVie’s Rinvoq, Pfizer’s ritlecitinib, and Incyte’s INCB54707 EXTON, Pa., June 15, 2022 /PRNewswire/ — Vitiligo is a disease that causes loss of skin color in patches when cells that produce melanin die or stop functioning.1 Spherix recently surveyed 101 US dermatologists […]
New Research on Alopecia Areata Reveals Vast Potential for Eli Lilly’s Recently Approved Olumiant Across Both the US and EU5, According to Spherix Global Insights
US and EU5 dermatologists report the availability of an oral JAK inhibitor would make a significant change in their treatment decisions moving forward EXTON, Pa., June 22, 2022 /PRNewswire/ — Spherix recently surveyed 200 EU-based dermatologists across France, Germany, Italy, Spain, and the UK and followed up with ten qualitative interviews to assess the current and future […]
Novartis’ Cosentyx and Eli Lilly’s Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen’s Tremfya and AbbVie’s Skyrizi Are Picking Up Steam, Spherix Reports
Rheumatologists are more likely than PsA-treating dermatologists to cycle TNFs prior to introducing an alternative mechanism of action agent EXTON, Pa., June 14, 2022 / PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several large-scale patient audits focused on psoriatic arthritis (PsA) patients recently switched […]
